Pfizer Accelerates Launch of Breakthrough Oncology Pipeline in China with Talazoparib and Elranatamab

2022Year11Month8Recently, Pfizer held an event during the fifth China International Import Expo.“Science Wins, New Pfizer Shines”Pfizer Oncology New Pipeline Roundtable and Pfizer Urology & Hematology New Product Preview Ceremony. During the event, attendees engaged in in-depth discussions on Pfizer's innovative products and clinical treatment needs in areas such as prostate cancer, multiple myeloma, and breast cancer.Looking forward to Pfizer with great anticipationHeavyweight innovative products with dual mechanisms in the field of oncologyPARPInhibitorTalazoparibBispecific Antibody Developed in Global SynchronizationElranatamabTo help Chinese patients fight the most difficult-to-treat tumor diseases as soon as possible and extend their lives.

This roundtable meeting, conducted in a combined online and offline format, invited Professor Dingwei Ye, Vice President of Fudan University Shanghai Cancer Center, Professor Depei Wu, Director of the Hematology Department at the First Affiliated Hospital of Soochow University, Professor Xichun Hu, Director of the Medical Oncology Department at Fudan University Shanghai Cancer Center, Yiqin Wang, General Manager of Pfizer Global BioPharmaceuticals Commercial Group China Oncology Business Unit, and Chaohua Chen, General Manager of Pfizer (China) Research and Development Co., Ltd., to participate.

“Science Prevails, New Pfizer Shines Brightly”Group Photo of Guests at the Pfizer Oncology New Pipeline Vision Roundtable

“Guided by science and driven by innovation, Pfizer Oncology is always committed to the relentless effort of conquering difficult-to-treat cancers. Adhering to...‘Bringing life-changing breakthroughs to patients’Our mission is to continuously expand our product pipeline through global R&D innovation and strategic collaborations, bringing first-in-class and best-in-class products to Chinese patients in urgent need at an unprecedented speed, and jointly advancing the continuous optimization of oncology medical solutions.” Peng Zhenke, President of Pfizer Global Biopharmaceuticals Commercial Group, China Region, said:“Pfizer has accelerated the introduction of several innovative oncology drugs through the CIIE. This year, we are bringing two globally synchronized innovative R&D products that address specific clinical needs. We hope to leverage the spillover effects of the CIIE platform to promote resource connectivity, industrial integration, and innovation collaboration within the healthcare industry. Our goal is to enable more Chinese patients to access world-leading high-quality medical resources and achieve maximum treatment benefits.”

New Radiance——Pfizer Showcases Multiple Key Oncology Products at the World Expo 

Pfizer Brings Two Innovative R&D Products to the CIIE, Featuring a Dual Mechanism in the Prostate Cancer FieldPARPInhibitorTalazoparibTargeted therapies in the field of multiple myelomaBCMAAndCD3Bispecific AntibodyElranatamab. Both products are making their debut in Asia for the first time. In addition, Pfizer will also present a series of innovative advancements in the field of breast cancer.CDKIntroduction to the Development Progress of Inhibitor Combination Therapies.

Pfizer has an industry-leading portfolio of urogenital products for treatment worldwide. 100 Hundreds of thousands of patients. Prostate cancer is one of the most common malignant tumors in the male urinary and reproductive system. Among them, metastatic castration-resistant prostate cancer (mCRPC) is the end-stage of prostate cancer, with a high degree of malignancy, lack of effective treatment, poor prognosis, and a survival period of only13.4months, there is an extremely high unmet treatment need. AsTALAPRO-2One of the leading researchers in China, Professor Ye Dingwei, pointed out:“Seeing that it was just announced last monthTALAPRO-2 IIII am delighted by the positive results achieved in the recent study.TalazoparibIs the first to confirm that it can be used in combination with enzalutamidemCRPCPatients bring clinical benefitsPARPInhibitor. This meansmCRPCPatients are no longer limited by genetic testing, and this will also provide new and promising treatment options for first-line therapy. It is hoped that this product can enter China as soon as possible, allowing more patients to have innovative treatment options to prolong life.”

In recent years, significant progress has been made in malignant hematological tumors such as leukemia, lymphoma, and multiple myeloma, with the emergence of numerous new drugs being particularly noteworthy. Molecular targeted drugs have brought substantial changes to the treatment of hematological tumors, altering the overall treatment landscape. Multiple myeloma is the second most common hematological malignancy in many countries. The use of various novel drugs has significantly extended the overall survival of patients, but many still face the great challenge of relapse and refractory conditions. Professor Depei Wu proposed at the conference:“Clinical and pharmaceutical experts have been exploring the development of innovative drugs with new mechanisms and targets in the field of hematological oncology.2021At the end of the year, Pfizer developed Inotuzumab Ozogamicin targetedCD22TheADCDrug Approved in China, Bringing New Hope to Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia. Currently Being Developed by Pfizer, Inc.ElranatamabIs a targetedBCMAAndCD3A bispecific antibody for the treatment of adult patients with multiple myeloma. China has currently joinedElranatamabGlobal simultaneous development of multiple clinical studies. In the future, we hopeElranatamabTo be approved in China as soon as possible, to address the unmet clinical needs of Chinese patients with multiple myeloma.”

Breast cancer is the leading malignant tumor that seriously threatens the health of women in China, with an increasing incidence rate year by year, posing a severe threat to women's health. Pfizer has been committed to promotingHR+Development in Breast Cancer Diagnosis and Treatment: Pfizer Launches the World's FirstCDK4/6Inhibitor Ibrance®(Palbociclib) afterwards, Pfizer continues to seek further development of a broad range of cutting-edge therapies in the breast cancer product line. Professor Hu Xichun stated at the conference:“In recent years, the diagnosis and treatment level of breast cancer has been improving year by year, and its survival rate far exceeds that of other malignant tumors. At the same time,‘Precision Medicine’It has gradually received attention, and individualized treatment strategies will further improve the prognosis of breast cancer patients and enhance their quality of life. However, challenges and progress coexist; there are still unmet needs in the clinical treatment of advanced breast cancer: the five-year survival rate for advanced cases in China is only20%, the overall median survival time is2～3Year The research and development of innovative drugs and their effective clinical application remain the earnest expectations of numerous clinical and pharmaceutical professionals. In the future, we hope that more innovative drugs will benefit a wide range of breast cancer patients.”

Global Synchronization——Pfizer Support“Healthy China2030”Target Achievement

In the past30Over the years, Pfizer has successively introduced its subsidiaries15A range of anti-tumor products, covering areas such as breast cancer, lung cancer, hematological tumors, urological and gastrointestinal tumors, to2025In the year, Pfizer plans to introduce multiple new products or new indications into China to meet the clinical treatment needs of Chinese patients. Ms. Chen Chaohua said:“We are fortunate to be in the golden age of new drug development, where innovative drugs can save more patients' lives. As of2022Year11Month, Pfizer has a total of112IndividualInnovative drug projects entering the clinical research stage are underway, including dual mechanisms in the field of prostate cancer.PARPInhibitorTalazoparib, Targeted Therapies in the Field of Multiple MyelomaBCMAAndCD3Bispecific AntibodyElranatamab, and a new generationCDKInhibitor products, etc., we look forward to these innovative products helping more Chinese patients regain high-quality survival and life as soon as possible. We will also continue to practice‘Two80%’'s commitment to scientific research, incorporating more Chinese patients and researchers into global clinical development, and allowing more global R&D achievements to benefit China simultaneously.”

Oncology has always been a strategic focus for Pfizer. Over the years, Pfizer has been innovating, accelerating introductions, and strengthening its oncology portfolio across all areas, aiming to bring new treatments in sync with global standards and the hope of curing lives to cancer patients in China. Ms. Wang Yiqin stated:“To meet the unmet clinical needs of Chinese cancer patients and promote progress in related fields of diagnosis and treatment in China has always been Pfizer's fundamental commitment. Based on Pfizer's global advantages across various types of cancer, we will continue to accelerate the introduction of innovative global products into China. In close collaboration with the Chinese government, healthcare professionals, and all sectors of society, we will continuously improve the accessibility of cancer drugs. Pfizer will also continue to shoulder‘Science Prevails, Together We Overcome Cancer’The concept is dedicated to integrating global resource advantages and China's scientific innovation capabilities, bringing more breakthrough changes to Chinese cancer patients and assisting‘Healthy China2030’Planned Increase in Five-Year Overall Cancer Survival Rate15%Achievement of the goal!”

Note:TalazoparibAndElranatamabProducts such as these have not yet been approved for marketing in China.